4/10
08:05 am
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Medium
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
4/2
08:00 am
plrx
Pliant Therapeutics to Participate in Upcoming Investor Events
Low
Report
Pliant Therapeutics to Participate in Upcoming Investor Events
3/27
10:28 am
plrx
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference [Yahoo! Finance]
Low
Report
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference [Yahoo! Finance]
3/27
10:23 am
plrx
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
Low
Report
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
3/25
07:21 am
plrx
CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks [Yahoo! Finance]
High
Report
CMTA Board Evolution: Welcoming Bernard Coulie and Kevin Marks [Yahoo! Finance]
3/12
07:43 am
plrx
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
Low
Report
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis [Yahoo! Finance]
3/12
07:30 am
plrx
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
Low
Report
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
3/5
10:34 am
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target raised by analysts at Royal Bank of Canada from $50.00 to $54.00. They now have an "outperform" rating on the stock.
Low
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target raised by analysts at Royal Bank of Canada from $50.00 to $54.00. They now have an "outperform" rating on the stock.
2/28
01:10 pm
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
Neutral
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
2/28
10:57 am
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $50.00. They now have an "outperform" rating on the stock.
Low
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $50.00. They now have an "outperform" rating on the stock.
2/28
08:18 am
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
Medium
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.
2/27
04:10 pm
plrx
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results [Yahoo! Finance]
Low
Report
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results [Yahoo! Finance]
2/27
04:03 pm
plrx
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
Medium
Report
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
2/26
08:18 am
plrx
Pliant Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Pliant Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
2/26
08:00 am
plrx
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Pliant Therapeutics to Participate in Upcoming Investor Conferences
2/7
08:17 am
plrx
Pliant Therapeutics to Participate in Upcoming Investor Events [Yahoo! Finance]
Low
Report
Pliant Therapeutics to Participate in Upcoming Investor Events [Yahoo! Finance]
2/7
08:00 am
plrx
Pliant Therapeutics to Participate in Upcoming Investor Events
Low
Report
Pliant Therapeutics to Participate in Upcoming Investor Events
2/6
07:21 am
plrx
Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors [Yahoo! Finance]
Low
Report
Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors [Yahoo! Finance]
2/5
02:13 pm
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Needham & Company LLC from $45.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Needham & Company LLC from $45.00 to $38.00. They now have a "buy" rating on the stock.
2/5
08:03 am
plrx
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at HC Wainwright from $52.00 to $48.00. They now have a "buy" rating on the stock.
High
Report
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at HC Wainwright from $52.00 to $48.00. They now have a "buy" rating on the stock.
2/4
03:41 pm
plrx
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis [Yahoo! Finance]
High
Report
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis [Yahoo! Finance]
2/4
03:29 pm
plrx
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
High
Report
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis